Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
Journal of Hepatocellular Carcinoma · 2026-11 · Volume 13 · 1-16
DOI: 10.2147/jhc.s650816 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-11. Verfasst von Haixiong Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology (including Interventional Radiology, General Radiology, and PET/CT Center), Affiliated Cancer Hospital of Xiangya School of M…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology (including Interventional Radiology, General Radiology, and PET/CT Center), Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hun…
- Department of Radiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, 410005, People's Republic of China.
ORCID-Profile: Lian Jian, Hailan Li, Huaping Liu
Zitieren
APA
Yan, H., Dai, J., Jian, L., Yu, X., Li, H., & Liu, H. (2026). Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Journal of Hepatocellular Carcinoma, Volume 13, 1-16. https://doi.org/10.2147/jhc.s650816
Vancouver
Yan H, Dai J, Jian L, Yu X, Li H, Liu H. Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-16. doi:10.2147/jhc.s650816
BibTeX
@article{Yan2026,
author = {Yan, Haixiong and Dai, Jiashun and Jian, Lian and Yu, Xiaoping and Li, Hailan and Liu, Huaping},
title = {Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--16},
doi = {10.2147/jhc.s650816}
}
EUVIMED